In this review, we explore current clinical and preclinical evidence that supports the potential use of EGFR inhibitors to address pain and morphine tolerance in oral cancer, in addition to their established role as effective anticancer agents. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.